| S no. |
Lesion |
No. Of total cases |
No. Of positive cases |
Cumulative score |
| Weakly reactive |
Moderately reactive |
Highly reactive |
Mean ± sd |
| 0-3 |
7-apr |
>8 |
| Group I |
Plemorphic adenoma |
|
|
|
|
|
|
| Benign |
8 |
8 |
3 |
2 |
3 |
5.88 ± 3.271 |
| Malignant |
Peripheral mucoepidermoid carcinoma |
5 |
5 |
- |
- |
5 |
10.4 ± 3.05 |
| Central mucoepidermoid carcinoma |
4 |
4 |
- |
3 |
1 |
6.50 ± 3.786 |
| Adenocarcinoma nos |
2 |
2 |
- |
1 |
1 |
6 ± 2.828 |
| PLGA |
1 |
1 |
1 |
- |
- |
2 |
| Total |
12 |
12 |
1 |
4 |
7 |
7.66 ± 3.91 |
A total of 20 cases formed the study group out of which Group I (Benign) comprising of 8 cases and group II (Malignant) comprising of 12 cases were each
immunohistochemically stained for podoplanin. All 8 cases of group I were positive and expression varied from weak to intense with 3 cases showing strong expression. In
group II, all 12 cases were positive and the expression varied from weak to high with 7 cases showing strong positive podoplanin expression. Overall, malignant tumours
showed a more intense podoplanin expression compared to benign tumours. |
